Scope and Claims Analysis for US Patent 12,472,156 (Dextromethorphan Hydrobromide + Bupropion HCl for Alzheimer’s Agitation) and the US Patent Landscape

US Patent 12,472,156 is a method-of-treatment patent that targets a staged, two-phase dextromethorphan/bupropion dosing regimen for agitation associated with Alzheimer’s disease. The claims are tightly constrained by: (i) patient population definitions and washout/concomitant-therapy exclusions, (ii) a specific one-week “initiation” schedule switching to a twice-daily schedule, and (iii) fixed dose strengths and release characteristics for dextromethorphan and bupropion in a first immediate-release dextromethorphan dosage form followed by a second sustained-release bupropion dosage form. The estate is structurally built for blocking future ANDA/abbreviated pathways through claim hooks on clinical inclusion criteria, dosing titration, and release profile rather than on a simple composition per se.

How broad are the claims in US 12,472,156 for treating agitation in Alzheimer’s disease?

Answer: The effective scope is narrow to a specific treatment algorithm and product dosing strengths: a first dosage form with 30 mg dextromethorphan HBr (immediate-release dextromethorphan) plus 105 mg bupropion HCl given once daily for one week, then twice daily for one week; followed by a second dosage form with 45 mg dextromethorphan HBr plus 105 mg bupropion HCl with sustained-release bupropion, dosed twice daily for at least one week (and at least three weeks in dependent claim 3).

Core independent claim 1 elements (claim “spine”)

Claim 1 requires all of the following:

Indication: “agitation associated with Alzheimer’s disease.”
Staged schedule:
- “first dosage form” administered once daily for one week, then
- twice daily for one week.
Drug actives and dose levels (exact):
- dextromethorphan 30 mg dextromethorphan hydrobromide (or salt/free-base equivalents by molar equivalence), and
- bupropion 105 mg bupropion hydrochloride (or salt/free-base equivalents by molar equivalence).
Release character: first dosage form provides immediate release of the dextromethorphan.

These four constraints drive the claim’s narrowing effect. Even if a competitor matches dextromethorphan and bupropion in the right ratio, changes to schedule, dose strengths, or release characteristics can move outside the claim.

Dependent claim expansion (claims 2 and 3)

Claim 2 adds a second dosage form after completion of the first two one-week phases:

Second dosage form: twice daily for at least one week
Second dosage form has:
- dextromethorphan 45 mg (hydrobromide or molar-equivalent salt/free-base) and
- bupropion 105 mg (hydrochloride or molar-equivalent salt/free-base)
Release character: second dosage form provides sustained release of bupropion

Claim 3 tightens the duration:

second dosage form twice daily for at least three weeks

Demographic/diagnostic and exclusion filters (claims 4–12)

Claims 4–12 further narrow who qualifies for the method:

Age: 65–90 years (claim 4)
Alzheimer’s “probable” definition: 2011 NIA-AA criteria (claim 5)
Agitation operational definition: IPA provisional definition of agitation (claim 6)
MMSE threshold: 10–24 (claim 7)
NPI agitation/aggression domain: score ≥ 4 (claim 8)
Setting: community dwelling (claim 9)
Concomitant exclusions:
- no concomitant SSRI (claim 10)
- no concomitant serotonin-and-norepinephrine inhibitor (claim 11)
Excludes alternative dementia type: not receiving dementia “of non-Alzheimer’s type” (claim 12)

This cluster is a strong litigation lever because it makes infringement dependent on treatment of a specifically characterized cohort under specific exclusions. A generic or originator attempting “non-infringing” practice may still be at risk if labeling, clinical protocols, or real-world implementation track these parameters.

Additional claim hooks on release profile (claims 13–14)

Claim 13: both first and second dosage forms provide sustained release of bupropion
Claim 14: both first and second dosage forms provide immediate release of dextromethorphan

These are important because they offer alternate infringement pathways tied to how release is structured in each phase. In practice, if a competitor’s formulation differs in release architecture for either component, the scope can hinge on these dependent alternatives.

Dose strength specificity (claims 15–18)

Claims 15–18 lock the formulation features to exact dose amounts for each phase:

Claim 15: first dosage form contains 30 mg dextromethorphan HBr
Claim 16: first dosage form contains 105 mg bupropion HCl
Claim 17: second dosage form contains 45 mg dextromethorphan HBr
Claim 18: second dosage form contains 105 mg bupropion HCl

These dependent claims reduce arguments about “range” equivalence. If the competitor’s strengths deviate (even slightly), coverage may be lost unless doctrine-of-equivalents arguments are available.

What is the practical clinical “algorithm” protected by US 12,472,156?

Answer: A two-step titration to twice-daily maintenance for Alzheimer’s agitation, using a first immediate-release dextromethorphan phase at 30/105 mg (once daily then twice daily for one week each), followed by a second phase at 45/105 mg with sustained-release bupropion, dosed twice daily for at least one week (and at least three weeks in a dependent claim).

Treatment timeline in the claim set

Phase	Dosage form	Dosing frequency	Timing	Dextromethorphan (HBr)	Bupropion (HCl)	Release requirement
First	“first dosage form”	once daily	1 week	30 mg	105 mg	immediate release of dextromethorphan
Transition	“first dosage form”	twice daily	1 week	30 mg	105 mg	immediate release of dextromethorphan
Second	“second dosage form”	twice daily	≥ 1 week	45 mg	105 mg	sustained release of bupropion
Second (dependent)	“second dosage form”	twice daily	≥ 3 weeks	45 mg	105 mg	sustained release of bupropion

Patient selection and exclusions embedded in infringement

The method is further constrained to:

elderly cohort (65–90),
probable Alzheimer’s disease per 2011 NIA-AA criteria,
agitation per IPA provisional definition,
MMSE 10–24,
NPI-Agitation/Aggression domain ≥ 4,
community dwelling,
no concomitant SSRI and no concomitant SNRIs,
no non-Alzheimer dementia.

This means the claim set is written as an evidence-and-protocol dependent method, not just a therapeutic “treat agitation” broad concept.

Which parts of the claim language are most vulnerable to non-infringing design-around?

Answer: The most design-around-sensitive elements are schedule (once daily for one week then twice daily for one week), exact dose strengths (30/105 then 45/105), and the formulation release characterization (immediate-release dextromethorphan in phase 1 and sustained-release bupropion in phase 2). The patient-selection and concomitant exclusions also create practical compliance and evidentiary pathways.

Design-around hotspots

Changing titration schedule
Any deviation from “once daily for one week” then “twice daily for one week” removes an essential element of claim 1.
Changing dose strengths
Claims 15–18 make dose amounts more explicit. If a competitor uses different mg strengths (not merely different salt forms that are molar equivalents), it likely exits the literal scope.
Changing release profiles
Claim 1 requires immediate release of dextromethorphan in the first dosage form. Claim 2 requires sustained release of bupropion in the second dosage form. Release architecture is a frequent formulation engineering variable.
Patient selection/exclusion elements
If a competitor pursues a different indicated cohort (or a different clinical protocol) that does not match the NIA-AA “probable” framework, MMSE range, NPI cutoff, or concomitant therapy restrictions, it may reduce direct method infringement exposure. The tight operational definitions are intended to track how trials and prescribing are implemented.

What does the claim set imply about formulation composition vs method-of-use coverage?

Answer: The patent is drafted as method-of-treatment, but it embeds formulation-defining features (dose strengths, salt forms, and release characteristics). This gives it “composition-like” traction for litigation while still targeting clinical actions.

How the formulation is used in claims

Salt forms are allowed as “molar equivalent” substitutes, which broadens beyond the literal “hydrobromide” and “hydrochloride” labels.
Release characteristics are used as operational requirements tied to each dosage form phase.
Strength-specific dependent claims create a clear evidentiary target for product composition.

Litigation implication

Even without a composition claim, proving a method requires showing administration of the specific dosage forms with the specified release properties. For NDA/labeling, the “how used” design is therefore central.

What is the likely patent landscape around this mechanism and dosage algorithm in the US?

Answer: The landscape should be evaluated as a combination of (i) formulation release patents and (ii) method-of-use and protocol/titration patents. For this specific dose-and-release algorithm, the claims read like they are designed to cover the clinical regimen and the corresponding product architecture. The US patent number you provided (12,472,156) is a single datapoint; a complete landscape requires the full family, continuations, related patents on similar dosage algorithms, and Orange Book linkages for the corresponding NDA product.

How to structure the landscape search (what the claims suggest)

To build a usable US landscape from the claim language alone, the relevant search axes are:

Active combination: dextromethorphan + bupropion (including salt forms and molar equivalence scope)
Release architecture: immediate vs sustained release assignments by component and by phase
Titration protocol: staged one-week initiation and subsequent maintenance schedule
Clinical definitions: NIA-AA (2011 probable), IPA provisional agitation, MMSE 10–24, NPI agitation/aggression ≥ 4, community dwelling
Exclusion criteria: no SSRI and no SNRI co-therapy
Dose strengths: 30/105 then 45/105 mg across phases

A competitor facing such a regimen typically must clear overlapping patents across these axes, including any process or unit dosage form claims in the same family.

What is the scope of enforceability: direct infringement, inducement, and ANDA/label triggers?

Answer: Because the claims are methods that require a specific treatment schedule and patient-selection criteria, enforcement typically concentrates on:

evidence of clinician instruction consistent with the regimen,
product instructions, label, and trial protocol documents,
marketing materials used to induce use in the covered cohort,
and, in abbreviated pathways, labeling carve-ins or “skinny label” challenges if the proposed labeling authorizes the protected method.

Where enforcement leverage likely sits

Clinical endpoints and cohort definitions in claims 4–12: align to trial inclusion criteria and potentially to label language.
Dosing schedule: align to prescribing instructions and dose titration language.
Formulation release: aligns to product design and may be referenced in characterization, manufacturing specs, or regulatory submissions.

How would claim 12 (“not receiving a concomitant serotonin and norepinephrine inhibitor” and “not receiving a concomitant SSRI”) affect infringement analysis?

Answer: It creates a gating element tied to the patient’s concurrent medication. If a real-world or trial population includes SSRI/SNRI co-therapy, the direct match to claims 10–11 becomes less certain for those patients. That can be used to argue non-infringement for patients outside the claim-defined exclusion rules. Conversely, if the covered product’s labeling or risk management directs avoidance of SSRIs/SNRIs (or trials excluded them), infringement evidence becomes stronger.

What is the “dose form” boundary in the claims: are the two dosage forms separately defined?

Answer: Yes. Claim 1 defines a “first dosage form” with specific dextromethorphan immediate release and 30/105 mg levels, while claim 2 defines a “second dosage form” with 45/105 mg levels and sustained release of bupropion. Dependent claims further add alternative release assignments (“both phases” for bupropion or dextromethorphan).

How does the claim drafting constrain generic or alternative formulations?

Answer: It forces the generic to match more than drug composition. The generic must match the staged regimen and align release behavior to each phase. For a generic to be positioned as a complete substitute without infringing, it would need to avoid at least one essential element of each independent claim path:

timing and dosing schedule, or
dose strengths per phase, or
release assignment for dextromethorphan and bupropion.

If a generic seeks to avoid infringement by using different release profiles, it risks losing therapeutic equivalence if the required pharmacokinetics differ. If it changes dosing strength, it risks label rejection or bioequivalence failures.

What patents protect the same clinical use more broadly: method-of-use vs formulation patents?

Answer: The claims here are method-of-use, but the inclusion of mg strengths and release requirements overlaps with the territory of formulation and delivery-system patents. The practical protection stack for the same drug combination typically includes:

formulation patents (release control, matrix design, granulation),
device-like or unit dosage form patents (tablet architecture, coated pellets, multipart systems),
and protocol patents (titration and patient selection).

US 12,472,156 sits at the interface: it is a method claim that requires formulation characteristics as claim elements.

What patent expiration and exclusivity questions matter for a freedom-to-operate view?

Answer: Expiration and exclusivity are driven by the patent’s filing/priority data, family structure, and any pediatric or PTA adjustments, plus the relevant FDA exclusivities (if applicable). The claim text alone does not provide any expiration or exclusivity timeline.

Key Takeaways

US 12,472,156 protects a two-phase titration regimen for Alzheimer’s agitation using dextromethorphan + bupropion with fixed strengths (30/105 mg then 45/105 mg) and defined release characteristics (phase 1: immediate-release dextromethorphan; phase 2: sustained-release bupropion).
Independent claim 1 is narrowed by schedule, dose strengths, and release profile; dependent claim 2 adds the second phase and dose upgrade.
Claims 4–12 add a tight patient-definition and exclusion framework (NIA-AA probable, IPA agitation, MMSE 10–24, NPI agitation/aggression ≥ 4, community dwelling, no SSRI/SNRI, no non-Alzheimer dementia).
Dependent claims 13–14 and 15–18 add additional release-scope hooks and explicit strength limitations, increasing evidentiary specificity in infringement.
The design-around risk for a competitor is highest if it matches the dosing algorithm and release architecture. The lowest-risk non-infringing path would be to avoid at least one essential element, especially schedule, dose strengths, or release assignment.

FAQs

Does US 12,472,156 cover only the exact 30 mg/105 mg and 45 mg/105 mg strengths?
Claims 15–18 explicitly tie the dosage forms to those mg amounts; the independent claims allow molar-equivalent salts/free bases but not different non-equivalent strengths.
Can a formulation with sustained-release dextromethorphan avoid claim 1?
Claim 1 requires immediate-release dextromethorphan in the first dosage form, so changing the dextromethorphan release to sustained-release is a likely escape from literal scope.
Are patient-selection criteria (MMSE, NPI, NIA-AA) required for infringement?
As written, claims 4–12 incorporate those limitations, so satisfying them is required for a method that falls within those dependent claim scopes.
Is the second dosage form’s duration flexible under claim 2?
Claim 2 requires at least one week; claim 3 tightens to at least three weeks.
What is the fastest way for a generic developer to assess risk from this patent?
Map the candidate product’s dosing schedule, dose strengths per phase, and release profile against the staged algorithm and then test whether label or intended patient population matches the defined cohort and exclusion criteria.

References

No sources were cited because only the claim text was provided.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Axsome	AUVELITY	bupropion hydrochloride; dextromethorphan hydrobromide	TABLET, EXTENDED RELEASE;ORAL	215430-002	Apr 30, 2026		RX	Yes	No	12,472,156	⤷ Start Trial				THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE	⤷ Start Trial
Axsome	AUVELITY	bupropion hydrochloride; dextromethorphan hydrobromide	TABLET, EXTENDED RELEASE;ORAL	215430-001	Aug 18, 2022		RX	Yes	Yes	12,472,156	⤷ Start Trial				THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER’S DISEASE	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2014346807	⤷ Start Trial
Australia	2015350559	⤷ Start Trial
Australia	2018203638	⤷ Start Trial
Australia	2019201548	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 12,472,156

Which drugs does patent 12,472,156 protect, and when does it expire?

Summary for Patent: 12,472,156